Core Viewpoint - The company announced a downward adjustment of the conversion price for its convertible bonds, effective from February 4, 2026, following shareholder approval on February 2, 2026 [1] Group 1 - The conversion price of the "Meinuo Convertible Bonds" has been revised from 25.68 CNY per share to 21.28 CNY per share [1] - The conversion of the "Meinuo Convertible Bonds" was suspended on February 3, 2026, and will resume on February 4, 2026 [1]

Core Viewpoint - The company Minohua (603538) announced a downward adjustment of the conversion price for its convertible bonds, effective from February 4, 2026, following shareholder approval on February 2, 2023 [1] Group 1 - The conversion price for "Minohua Convertible Bonds" has been revised from 25.68 yuan per share to 21.28 yuan per share [1] - The adjustment will take effect from February 4, 2026, after the bonds were suspended from conversion on February 3, 2023 [1]

Core Viewpoint - Ningbo Menohua Pharmaceutical Co., Ltd. is relocating its office due to business development and management needs, with the new address provided in the announcement [1]. Group 1: Office Relocation - The company is moving its office from Ningbo High-tech Zone to a new location at 777 Jinghua Road, Building 1, Meixu Street, Ningbo High-tech Zone [1]. - The postal code for the new office is 315000, and the investor contact number remains unchanged [1]. Group 2: Convertible Bonds Information - The company issued 520 million yuan of convertible bonds on January 14, 2021, with a maturity of six years and an initial conversion price of 37.47 yuan per share [3]. - The bond's conversion price has been adjusted multiple times, with the latest adjustment bringing it down to 25.68 yuan per share as of June 24, 2025 [5][6]. Group 3: Downward Adjustment Conditions - The company has outlined conditions under which the conversion price of the bonds may be adjusted downward, specifically if the stock price falls below 90% of the current conversion price for at least 15 out of 30 consecutive trading days [7]. - As of January 30, 2026, the stock price has been below the threshold of 23.11 yuan, indicating a potential trigger for the downward adjustment of the conversion price [9].

"美诺转债"存续的起止日期为 2021 年 1 月 14 日至 2027 年 1 月 13 日，转 股期起止日期为 2021 年 7 月 20 日至 2027 年 1 月 13 日，初始转股价格为 37.47 元/股。 （二）可转换公司债券转股价格历次调整情况 | | | 宁波美诺华药业股份有限公司 关于"美诺转债"预计满足转股价格向下修正条件的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、可转换公司债券基本情况 （一）可转换公司债券发行上市概况 经中国证券监督管理委员会《关于核准宁波美诺华药业股份有限公司公开发 行可转换公司债券的批复》（证监许可[2020]2377 号）核准，2021 年 1 月 14 日， 宁波美诺华药业股份有限公司（以下简称"公司"）公开发行 52,000 万元可转换 公司债券，共发行 520 万张，每张面值 100 元，期限 6 年。2021 年 2 月 4 日起， 上述可转换公司债券在上海证券交易所挂牌交易，转债简称"美诺转债"，转债 代码"113618"。 1、2021 年 12 ...

办公场所/联系地址：宁波市高新区梅墟街道菁华路 777 号 1 号楼 邮编：315000 投资者联系电话：0574—87916065 公司网址：https://www.menovopharm.com 投资者邮箱：nbmnh@menovopharm.com | 证券代码：603538 | 证券简称：美诺华 | 公告编号：2026-014 | | --- | --- | --- | | 转债代码：113618 | 转债简称：美诺转债 | | 宁波美诺华药业股份有限公司 关于公司办公场所迁址的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 宁波美诺华药业股份有限公司（以下简称"公司"）因业务发展和经营管理 需要，办公场所由宁波市高新区扬帆路 999 弄宁波研发园 B1 幢 12A 层、14 层搬 迁至宁波市高新区梅墟街道菁华路 777 号 1 号楼，其他联系方式均未发生变更， 现将新办公场所地址及联系方式公告如下： 董事会 2026 年 1 月 31 日 1 特此公告。 宁波美诺华药业股份有限公司 ...

（编辑 袁冠琳） 证券日报网讯 1月29日，美诺华发布公告称，公司控股子公司安徽美诺华药物化学有限公司近日收到安 徽省工业和信息化厅、安徽省财政厅、国家税务总局安徽省税务局联合颁发的《高新技术企业证书》， 证书编号为GR202534003865，发证时间为2025年10月28日，有效期为三年。安徽美诺华自获得高新技 术企业认证通过后三年内（即2025年、2026年、2027年）可享受国家关于高新技术企业的相关优惠政 策，即按15%的税率缴纳企业所得税。 ...

Core Viewpoint - Meihua (603538.SH) announced that its subsidiary, Anhui Meihua Pharmaceutical Chemistry Co., Ltd., has received the "High-tech Enterprise Certificate" from the Anhui Provincial Department of Industry and Information Technology, Anhui Provincial Department of Finance, and the State Taxation Administration of Anhui Province, valid for three years starting from October 28, 2025 [1] Group 1 - Anhui Meihua's high-tech enterprise recognition is a renewal of its previous certificate, which expired [1]

| 证券代码：603538 | 证券简称：美诺华 | 公告编号：2026-012 | | --- | --- | --- | | 转债代码：113618 | 转债简称：美诺转债 | | 宁波美诺华药业股份有限公司 关于控股子公司通过高新技术企业重新认定的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日,宁波美诺华药业股份有限公司（以下简称"公司"）控股子公司安徽美 诺华药物化学有限公司（以下简称"安徽美诺华"）收到安徽省工业和信息化厅、 安徽省财政厅、国家税务总局安徽省税务局联合颁发的《高新技术企业证书》， 证书编号为 GR202534003865，发证时间为 2025 年 10 月 28 日，有效期为三年。 2026 年 1 月 30 日 1 安徽美诺华的本次高新技术企业的认定在原证书有效期满后的重新认定，根 据《高新技术企业认定管理办法》、《中华人民共和国企业所得税法》等相关规定， 安徽美诺华自获得高新技术企业认证通过后三年内（即 2025 年、2026 年、2027 年）可享受国家关于高新技术企业的相关优惠政策 ...

Core Viewpoint - Ningbo Meinuo Pharmaceutical Co., Ltd. (referred to as "Meinuo") expects a significant increase in its 2025 annual performance, with net profit projected to reach between 100 million to 123 million yuan, representing a year-on-year increase of 49.69% to 84.11% [1] Financial Performance - The company anticipates a net profit attributable to shareholders of the parent company for 2025 to be between 100 million to 123 million yuan, which is an increase of 49.69% to 84.11% year-on-year [1] - The net profit after deducting non-recurring gains and losses is expected to be between 80 million to 95 million yuan, reflecting a year-on-year growth of 62.43% to 92.88% [1] Business Strategy - Meinuo's performance growth is primarily driven by an increase in operating revenue for 2025 [1] - The company adheres to a vertical integration strategy covering "pharmaceutical intermediates, raw materials, and formulations," serving major global markets and focusing on key therapeutic areas such as cardiovascular, central nervous system, antiviral, blood sugar reduction, and gastrointestinal treatments [1] - In 2025, Meinuo aims to leverage capital markets for "intrinsic growth + external expansion" to drive development, reinforcing its core business in specialty raw materials while expanding into upstream intermediate business and downstream formulation business [1] - The company is committed to continuous R&D innovation and business development, enhancing its integrated strategy and advancing the development and commercialization of cutting-edge pharmaceutical products [1]

资金面上看，美诺华近5日主力资金总体呈净流入状态，累计净流入2737.89万元，其中，上一交易日主 力资金全天净流入532.43万元。 融资融券数据显示，该股最新（1月26日）两融余额2.27亿元，其中，融资余额为2.27亿元，近5日融资 余额合计增加481.77万元，增幅为2.17%。（数据宝） （文章来源：证券时报网） 美诺华股价出现异动，截至今日9时58分，股价下跌5.16%，成交462.42万股，成交金额1.01亿元，换手 率为2.14%，公司发布的最新业绩预告显示，预计2025年实现净利润1.00亿元—1.23亿元，净利润同比 增长49.69%—84.11%。 证券时报·数据宝统计显示，今日公布2025年业绩预告公司中，截至发稿股价较为强势的有三生国健、 蓝特光学、芯源微等，股价分别上涨8.78%、8.36%、8.11%，股价跌幅较大的有淳中科技、新日股份、 富士莱等，分别下跌10.00%、8.64%、7.34%。 ...